Question · asked by 1 review

Omega‐3 vs placebo: Serious adverse events: cardiovascular events

Population
dialysis vascular access outcomes in AVG patients with ESKD
Intervention
Omega‐3
Comparison
placebo
Outcome
Serious adverse events: cardiovascular events

It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Omega‐3 fatty acids vs Placebo
Serious adverse events: cardiovascular events · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes serious adverse events: cardiovascular events compared with placebo (very low certainty).
Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease (2018) · Cochrane Headline outcomes only
no estimate extracted4 studies · 261 participantsVery low

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.